These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 34866539)

  • 1. What are the key challenges in the pharmacological management of cholangiocarcinoma?
    Ledenko M; Patel T
    Expert Opin Pharmacother; 2022 Apr; 23(5):531-533. PubMed ID: 34866539
    [No Abstract]   [Full Text] [Related]  

  • 2. Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future.
    Rizzo A; Ricci AD; Cusmai A; Acquafredda S; De Palma G; Brandi G; Palmiotti G
    Curr Oncol; 2022 Jan; 29(2):551-564. PubMed ID: 35200550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The future is here-targeted therapies are coming of age in biliary tract cancers.
    Neureiter D; Ocker M
    Chin Clin Oncol; 2023 Jun; 12(3):20. PubMed ID: 37211774
    [No Abstract]   [Full Text] [Related]  

  • 4. Dual HER2 Blockade: An Emerging Option in Metastatic Biliary Tract Cancer?
    Ricci AD; Rizzo A
    Medicina (Kaunas); 2021 Nov; 57(12):. PubMed ID: 34946246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular perturbations in cholangiocarcinoma: Is it time for precision medicine?
    Braconi C; Roessler S; Kruk B; Lammert F; Krawczyk M; Andersen JB
    Liver Int; 2019 May; 39 Suppl 1():32-42. PubMed ID: 30829432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic therapy of cholangiocarcinoma: From chemotherapy to targeted therapies.
    Schweitzer N; Vogel A
    Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):345-53. PubMed ID: 25966433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy in Biliary Tract Cancers: Where Are We?
    Kalyan A; Khosla H; Kim RD
    Curr Oncol Rep; 2022 Dec; 24(12):1821-1828. PubMed ID: 36192517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The state of therapy modalities in clinic for biliary tract cancer.
    Chen W; Hu Z; Song J; Wu Y; Zhang B; Zhang L
    Front Biosci (Landmark Ed); 2022 Jun; 27(6):185. PubMed ID: 35748261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study).
    Leone F; Marino D; Cereda S; Filippi R; Belli C; Spadi R; Nasti G; Montano M; Amatu A; Aprile G; Cagnazzo C; Fasola G; Siena S; Ciuffreda L; Reni M; Aglietta M
    Cancer; 2016 Feb; 122(4):574-81. PubMed ID: 26540314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemoresistance and resistance to targeted therapies in biliary tract cancer: what have we learned?
    Mayr C; Kiesslich T; Modest DP; Stintzing S; Ocker M; Neureiter D
    Expert Opin Investig Drugs; 2022 Feb; 31(2):221-233. PubMed ID: 35098846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring Molecular Mechanisms in the Second-Line Treatment of Biliary Tract Malignant Tumors.
    Liu Q; Zhang P; Li Q
    Discov Med; 2024 Jan; 36(180):48-60. PubMed ID: 38273745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining biological agents and chemotherapy in the treatment of cholangiocarcinoma.
    Jensen LH; Jakobsen A
    Expert Rev Anticancer Ther; 2011 Apr; 11(4):589-600. PubMed ID: 21504326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses.
    Yoon JG; Kim MH; Jang M; Kim H; Hwang HK; Kang CM; Lee WJ; Kang B; Lee CK; Lee MG; Chung HC; Choi HJ; Park YN
    Hepatology; 2021 Oct; 74(4):1914-1931. PubMed ID: 33884649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrating cytotoxic, targeted and immune therapies for cholangiocarcinoma.
    Merters J; Lamarca A
    J Hepatol; 2023 Mar; 78(3):652-657. PubMed ID: 36400328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic therapy for hepatocellular carcinoma and cholangiocarcinoma.
    Chung V
    Surg Oncol Clin N Am; 2015 Jan; 24(1):187-98. PubMed ID: 25444475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Highlights of topic "Biochemical and molecular pathological aspects of cholangiocarcinoma".
    Murakami Y
    J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):359-61. PubMed ID: 24840727
    [No Abstract]   [Full Text] [Related]  

  • 17. Does aspirin use influence hepatocellular carcinoma and cholangiocarcinoma prognosis?
    Stefanini B; Tonnini M; Marseglia M; Tovoli F
    Expert Rev Anticancer Ther; 2022 Sep; 22(9):887-889. PubMed ID: 35866267
    [No Abstract]   [Full Text] [Related]  

  • 18. A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer.
    Furuse J; Okusaka T; Ohkawa S; Nagase M; Funakoshi A; Boku N; Yamao K; Yamaguchi T; Sato T
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):113-20. PubMed ID: 19404641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pemigatinib in Intrahepatic Cholangiocarcinoma: A Work in Progress.
    Gadaleta-Caldarola G; Rizzo A; Dadduzio V; Lombardi L; Gadaleta-Caldarola A; Infusino S; Cusmai A; Citrigno C; Palmiotti G
    Curr Oncol; 2022 Oct; 29(10):7925-7931. PubMed ID: 36290903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Photodynamic therapy in cholangiocarcinoma.
    Kahaleh M
    J Natl Compr Canc Netw; 2012 Oct; 10 Suppl 2():S44-7. PubMed ID: 23055215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.